Press Releases

 
Press Releases
Date Title and Summary View
Nov 27, 2012 MADISON, Wisc. (November 27, 2012) – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that Harry Palmin, President and CEO of Novelos, will present a corporate update at the Benchmark 2012 Micro Cap Discovery Investor Conf...
PDF
Nov 5, 2012 Initiates Build-out of Manufacturing Facility for I-124-CLR1404 (LIGHT) MADISON, Wisc. (November 5, 2012) – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced the closing of a private placement of e...
PDF
Oct 25, 2012 Expects Initial Imaging Results in First Quarter 2013 MADISON, Wisc. (October 25, 2012) – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that the University of Wisconsin Carbone Cancer Cente...
PDF
Oct 3, 2012 Cancer-Targeted PET Imaging, Therapeutic and Optical Imaging Compounds Offer Broad-Spectrum Diagnosis and Treatment of Solid Tumors MADISON, Wisc. (October 3, 2012) – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of canc...
PDF
Oct 2, 2012 MADISON, Wisc. (October 2, 2012) – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that Harry Palmin, President and CEO of Novelos, will present a corporate update at the 11th Annual BIO Investor Forum on Wednesday, Octob...
PDF
Sep 11, 2012 Additional Clinical Results Expected in Q1 2013 MADISON, Wisc. (September 11, 2012) – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that it has successfully completed the second cohort in a U.S...
PDF
Sep 7, 2012 Cancer-Targeted Therapeutic I-131-CLR1404 (HOT) and Diagnostic I-124-CLR1404 (LIGHT) Demonstrate Selective and Prolonged Uptake in a Range of Tumor Types MADISON, Wisc. (September 7, 2012) – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatme...
PDF
Sep 4, 2012 MADISON, Wisc. (September 4, 2012) – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that Harry Palmin, President and CEO of Novelos, will present at the Rodman & Renshaw 14th Annual Healthcare Conference on Tuesday, ...
PDF
Aug 28, 2012 Expects to File IND in Second Half of 2013 MADISON, Wisc. (August 28, 2012) – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that it is developing CLR1502 (GLOW2), a preclinical cancer-targe...
PDF
Jun 27, 2012 MADISON, WI, June 27, 2012 – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that Harry S. Palmin, President and CEO of Novelos, will present a corporate update at the LHA Life Sciences & Medical Technologies Virtual ...
PDF
Page: FirstPrevious ...
17
NextLast